Filter By Category
Archives
Share on -
CINPANEMAB
Generic Name: CINPANEMAB
ABSTRACT -
Cinpanemab (BIIB054) is a human monoclonal antibody that selectively binds pathological aggregated forms of alpha-synuclein, the protein that accumulates in Lewy bodies and Parkinson's disease pathology. It aims to clear alpha-synuclein aggregates and slow neurodegeneration in Parkinson's disease.
DOSAGE -
Administered intravenously in clinical trials; dose ranges from 250 to 1500 mg every 4 weeks; regimen per SPARK trial protocol.
SIDE EEFECTS -
- Infusion-related reactions
- Headache
- Fatigue
- Upper respiratory infections
- Arthralgia
ALLERGIC REACTIONS -
(These symptoms may indicate an allergic reaction and require medical attention.)
- Hypersensitivity infusion reactions
- Urticaria
- Angioedema
- Anaphylaxis (rare)
DRUG INTERACTIONS-
- Limited drug interaction data in Parkinson's population
- Concurrent dopaminergic therapy does not appear to have PK interaction
- Immunosuppressants not typically co-administered
PREAUTONS–
- Monitor for amyloid-related imaging abnormalities (ARIA) if applicable
- Neurological assessments (MDS-UPDRS) required for trial participation
- Long-term immunogenicity monitoring needed
- Pregnancy safety not established
WARNINGS –
- Phase II results did not show significant clinical benefit at interim analysis
- Investigational — not approved
- Infusion reactions require monitoring during and after infusion
Share on -
. Developed by